Is 18F-FDG PET/CT useful for imaging and management of patients with suspected occult recurrence of cancer?

Journal of Nuclear Medicine

Volumn 45, Issue 12, 2004, Pages 2045-2051

  Israel, Ora ^a,b   Mor, Maya ^a   Guralnik, Luda ^a   Hermoni, Nirit ^a   Gaitini, Diana ^a,b   Bar Shalom, Rachel ^a   Keidar, Zohar ^a,b   Epelbaum, Ron ^a,b  

^a RAMBAM MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Cancer recurrence; PET; PET CT; Tumor markers

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; BIOLOGICAL MARKER; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HUMAN; IMAGING SYSTEM; LUNG CANCER; MALE; OVARY CANCER; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; THYROID CANCER; TREATMENT PLANNING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; IMAGE PROCESSING; METABOLISM; METHODOLOGY; MIDDLE AGED; NEOPLASM; SCINTISCANNING; TUMOR RECURRENCE;

ADULT; AGED; BIOLOGICAL MARKERS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 16644363470     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Duffy MJ. Clinical uses of tumor markers: a critical review. Crit Rev Clin Lab Sci. 2001;38:225-262.
2. Sagar PM, Pemberton JH. Surgical management of locally recurrent rectal cancer. Br J Surg. 1996;83:293-304.
3. Bakalakos EA, Burak WE, Young DC, et al. Is carcino-embryonic antigen useful in the follow-up management of patients with colorectal liver metastases? Am J Surg. 1999;177:2-6.
4. Hida JI, Yasutomi M, Shindoh K, et al. Second-look operation for recurrent colorectal cancer based on carcinoembryonic antigen and imaging techniques. Dis Colon Rectum. 1996;39:74-79.
5. Torizuka T, Nobezawa S, Kanno T, et al. Ovarian cancer recurrence: role for whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2- deoxy-D-glucose. Eur J Nucl Med. 2002;29:797-803.
6. 18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol. 2001;19:414-419.
7. 18F-fluoro-2- deoxyglucose positron emission tomography in the evaluation of recurrent colorectal cancer. Anticancer Res. 2001;21:1375-1378.
8. Cook GI, Maisey MN, Fogelman I. Normal variants, artifacts and interpretative pitfalls in PET imaging with 18-fluoro-deoxyglucose and carbon-11 methionine. Eur J Nucl Med. 1999;26:1363-1378.
9. Kostakoglu L, Agress H, Goldsmith J. Clinical role of FDG PET in evaluation of cancer patients. Radiographics. 2003;23:315-340.
10. Beyer T, Townsend DW, Brun T, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med. 2000;41:1369-1379.
11. Bar-Shalom R, Yefremov N, Altman H, et al. The clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med. 2003;44:1200-1209.
12. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348:2500-2507.
13. Patt YZ, Podoloff DA, Curley S, et al. Technetium 99m-labeled IMMU-4, a monoclonal antibody against carcinoembryonic antigen for imaging of occult recurrent colorectal cancer in patients with rising serum carcinoembryonic antigen levels. J Clin Oncol. 1994;12:489-495.
14. Mangkharak J, Patanachak C, Podhisuwan K, et al. The evaluation of combined scintimammography and tumor markers in breast cancer patients. Anticancer Res. 1997;17:1611-1614.
15. Arulampalam THA, Costa DC, Loisidou M, et al. Positron emission tomography and colorectal cancer. Br J Surg. 2001;88:176-189.
16. Buccheri G, Ferrigno D. Serum biomarkers facilitate the recognition of earlystage cancer and may guide the selection of surgical candidates: a study of carcinoembryonic antigen and tissue polypeptide antigen in patients with operable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2001;122:891-899.
17. Zervos EE, Badgwell BD, Burak WE, et al. Fluorodeoxyglucose positron emission tomography as an adjunct to carcinoembryonic antigen in the management of patients with presumed recurrent colorectal cancer and nondiagnostic radiologic workup. Surgery. 2001;130:636-644.
18. Jadvar H, Fischman AJ. Evaluation of pancreatic carcinoma with FDG PET. Abdom Imaging. 2001;26:254-259.
19. Makhija S, Howden N, Edwards R, et al. Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review. Gynecol Oncol. 2002;85:53-58.
20. Sijmons EA, Heintz AP. Second look and second surgery: second chance or second best? Semin Oncol. 2000;19:54-61.
21. Wexner SD. Invited critique. Arch Surg. 1999;134:311-313.
22. Flamen P, Hoekstra OS, Homans F, et al. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). Eur J Cancer. 2001;37:862-869.
23. 18F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med. 2002;43:492-499.
24. Flanagan FL, Dehdashti F, Ogunbiyi OA, et al. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg. 1998;227:319-323.
25. 18F fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg. 1999;134:503-511.
26. Czernin J, Phelps ME. Positron emission tomography scanning: current and future applications. Annu Rev Med. 2002;53:89-112.